Catalyst View
Our reading of the numbers
Co-Founder and General Manager, Catalyst Performance
The June 2026 Complete Life Tables from the Department of Statistics confirm Singapore's life expectancy at 83.9 years for 2025, up from the preliminary 83.5 figure we cited last month. That is good news. The harder number has not moved: healthy life expectancy sits around 74. The last decade of a Singaporean's life is, on average, spent in poor health. We keep adding years to the end of the line. We have not yet changed what those years look like.
The statistic I think deserves the most attention this month is new to this hub: a 2024 meta-analysis in The Lancet Diabetes and Endocrinology found that between 25 and 39 percent of total weight lost on GLP-1 receptor agonists is lean mass, not fat. These medications are now mainstream, and the clinical framing around them focuses almost entirely on the number on the scale. It does not mention that a meaningful share of what disappears is the tissue that determines strength, metabolic rate, and fall risk at 70. Resistance training is not something people on GLP-1s should consider as a nice addition. For most of them, it is the essential second half of the protocol.
Two population figures compound that picture. The Asian Working Group for Sarcopenia's 2025 consensus found 16.5 percent of Asian adults over 60 already meet the diagnostic threshold, and lowered the recommended screening age to 50. Alongside that: 20.7 percent of Singapore citizens are now 65 or older, a figure set to reach 23.9 percent by 2030. The population most at risk of sarcopenia is the fastest-growing segment of this country. Earlier screening is not a clinical nicety. It is the gap between catching something reversible and managing something that has already compounded.
What we measure at Catalyst, the four pillars of body composition, cardiorespiratory fitness, stability, and strength, maps precisely to the gaps the data keeps surfacing. The 53 percent lower all-cause mortality in the highest cardiorespiratory fitness group is not a marginal finding. It is the kind of effect size that should determine how individuals and health systems allocate effort. The most important decade to act is not the one before a diagnosis. It is the one in front of you now.
Between 25 and 39 percent of the weight lost on GLP-1 medications is lean mass, not fat. Resistance training is the essential second half of that protocol.
